Evidence map›Paper›PMID 34511134›Full record

Trial reportLipids in health and disease2021

Effect of alirocumab on coronary plaque in patients with coronary artery disease assessed by optical coherence tomography.

Fei Gao, Zhi Jian Wang, Xiao Teng Ma, Hua Shen, Li Xia Yang, Yu Jie Zhou

2 registry-linked trialsOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Lipids in health and disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 23 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 5 pooled it
6.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06520904 phase4recruitingstarted 2024, after this paper: background citation

Effect of PCSK9 Inhibitors on Coronary Atherosclerotic Plaques Derived From Optical Coherence Tomography in Patients With Premature Coronary Artery Disease: a Randomized Controlled Trial

Ran2024Enrolled396Registered outcomes6Posted comparisons0ConditionsCoronary Artery Disease, Optical Coherence TomographyArmsPCSK9 inhibitor, Statin
PMID 33755142PMID 37666281PMID 31504418PMID 33303068PMID 33714389PMID 33865792PMID 35368058PMID 35431172PMID 26655874PMID 27846344PMID 30553686PMID 31112213other papers from this trial
Open the trial in the graph
NCT04851769 phase4completednot on this map

Impact of PCSK9 Inhibitors on Coronary Plaque Composition and Vulnerability in Patients With Coronary Artery Disease Assessed by Optical Coherence Tomography

TypeinterventionalSponsorBeijing Anzhen HospitalRan2019 to 2021Enrolled60ConditionsRandomized Controlled TrialsArmsPCSK9 inhibitor plus statin, standard statin therapy, Coronary imaging follow-up
3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 5 syntheses or guidelines pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease: A Network Meta-analysis.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2026 · on this map
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Fei GaoDepartment of Cardiology, An Zhen Hospital, Capital Medical University, Anzhenli avenue, Chao Yang district, Beijing, 100029, China. fgaomd@163.com.
Zhi Jian WangDepartment of Cardiology, An Zhen Hospital, Capital Medical University, Anzhenli avenue, Chao Yang district, Beijing, 100029, China.
Xiao Teng MaDepartment of Cardiology, An Zhen Hospital, Capital Medical University, Anzhenli avenue, Chao Yang district, Beijing, 100029, China.
Hua ShenDepartment of Cardiology, An Zhen Hospital, Capital Medical University, Anzhenli avenue, Chao Yang district, Beijing, 100029, China.
Li Xia YangDepartment of Cardiology, An Zhen Hospital, Capital Medical University, Anzhenli avenue, Chao Yang district, Beijing, 100029, China.
Yu Jie ZhouDepartment of Cardiology, An Zhen Hospital, Capital Medical University, Anzhenli avenue, Chao Yang district, Beijing, 100029, China. azzyj12@163.com.
Capital Medical University · CNBeijing Anzhen Hospital · CNBeijing Chao-Yang Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors have been demonstrated to produce significantly greater reduction in LDL cholesterol levels and cardiovascular events than standard statin therapy. However, evidence on the impact of PCSK9 inhibitors on coronary plaque composition and morphology is limited.

methodsIn this open-label randomized study, eligible patients with intermediate coronary lesions and elevated LDL cholesterol values were randomized to either alirocumab 75 mg Q2W plus statin (atorvastatin 20 mg/day or rosuvastatin 10 mg/day) therapy or standard care. Optical coherence tomography (OCT) assessments for target lesions were obtained at baseline and at 36 weeks of follow-up.

resultsLDL cholesterol levels were significantly decreased in both the alirocumab and standard care arms, whereas the absolute reduction in LDL cholesterol was significantly greater in patients treated with alirocumab (1.72 ± 0.51 vs. 0.96 ± 0.59, P < 0.0001). Compared with standard care, the addition of alirocumab to statins was associated with significantly greater increases in minimum fibrous cap thickness (18.0 [10.8-29.2] μm vs 13.2 [7.4-18.6] μm; P = 0.029), greater increases in minimum lumen area (0.20[0.10-0.33] mm

conclusionsThe addition of alirocumab to statins can not only provide additional LDL cholesterol lowering effects but also have a potential role in promoting a more stable plaque phenotype.

trial registrationClinicalTrials.gov Identifier: NCT04851769 . Registered 2 Mar 2019.

Indexed as

AgedAntibodies, Monoclonal, HumanizedAnticholesteremic AgentsAtorvastatinCholesterol, LDLCoronary Artery DiseaseDrug SynergismDrug Therapy, CombinationFemaleFollow-Up StudiesGene ExpressionHumansMaleMiddle AgedPCSK9 InhibitorsPlaque, AtheroscleroticalirocumabAntibodies, Monoclonal, HumanizedAnticholesteremic AgentsAtorvastatinCholesterol, LDLPCSK9 InhibitorsPCSK9 protein, humanProprotein Convertase 9Rosuvastatin CalciumCoronary artery diseaseCoronary plaqueOptical coherence tomographyPCSK9 inhibitorsStatins

Identifiers

PMID34511134
PMCPMC8436513
OpenAlexW3182723539

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.